Kornimate/medical-research-clean huggingface dataset:
honey used as adjunct therapy to tylenol for post-op tonsillectomy patients

Conditions: Tonsillectomy

Summary: tonsillectomies are the second most common surgery with over half a million procedures in the united states for 2006. tonsillectomies are considered a painful surgical procedure performed on children resulting in pain and nausea/vomiting for up to 7 days postoperatively. up until recently, doctors have been prescribing upwards of ten days' worth of opioid pain medication for children following tonsillectomies due to the high incidence of pain expected afterwards. effective july 1st, 2018, new laws regarding opioid restrictions came into place that restricted doctor's abilities to write for more than three days' worth of opioid pain medication without having to fill out sizeable amounts of additional paperwork. this law was put in place to combat the ongoing opioid epidemic that plagues this country. what the investigators are left with for the treatment of pain following these procedures are simply tylenol and motrin with a limited amount of opioid. with this being considered a highly painful surgery with a difficult recovery, more options are needed to effectively treat pain and reduce the incidence of emergency room visits and phone calls to the clinic regarding pain control in the postoperative period. studies in europe have shown that honey is an effective adjunct treatment option in the reduction of pain in pediatric postoperative tonsillectomies. these studies are few and far between and more research needs to be conducted to validate these claims particularly in the united states where research on this subject has been extremely limited. further, the extent to which families and health care providers in the united states would be receptive to using honey for children's postoperative pain is unclear since honey is considered a complementary and alternative medicine (cam) intervention.


Eligibility criteria:
inclusion criteria: * english-speaking families * male or female * 2-17 years old undergoing a routine tonsillectomy procedure. * english speaking families in the waiting room whose children are having any type of surgery during the time period we are enrolling the tonsillectomy patients. exclusion criteria: * subjects will be excluded for any of the following reasons: any child undergoing or has already undergone a tonsillectomy who has a genetic syndrome or developmental disability (e.g., trisomy 21, angelman syndrome, etc.) which could impact the course of postoperative pain management. * any child who has an allergy to honey. * non english speaking families.

Keywords: honey pediatrics post-operative
evaluation of the metastasis and recurrence of prostate cancer

Conditions: Prostate Cancer (Diagnosis); Prostate Cancer Metastatic; Prostate Cancer Recurrent; Prostate Cancer Stage

Summary: this study aims to use the new molecular probe 18f-psma for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.by compared with the conventional imaging methods (whole body bone scintigraphy and mri) and molecular imaging methods (11c-choline pet/ct),we hope to find the advantages of 18f-psma pet/ct in the diagnosis and metastases of prostate cancer, and lay the foundation for the further clinical transformation.

this study aims to use the new molecular probe 18f-psma for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.by compared with the conventional imaging methods (whole body bone scintigraphy and mri) and molecular imaging methods (11c-choline pet/ct),we hope to find the advantages of 18f-psma pet/ct in the diagnosis and metastases of prostate cancer, and lay the foundation for the further clinical transformation.and make some comparison with those 3 methods.

Eligibility criteria:
inclusion criteria: 1. patients with initial diagnosis of prostate cancer; 1）t2 stage: psa\>20ng/ml, gleason score \>= 8; 2）t3 or t4 stage; 3）the imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity. 2. patients with biochemical recurrent prostate cancer; 1）after the rrp surgery, the serum psa was over 0.2 ng/ml in two consecutive sera; 2）after the radiotherapy: the lowest psa is up to 2 ng/ml. 3. patients with crpc. 1）the serum testosterone is in the castration level (\ 2ng/ml(the interval is one week); 3）the continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks; 4）despite the continued standard androgen deprivation therapy, the psa is still progressing. exclusion criteria: 1. patients who are unwilling to participate in the study or unwilling to sign the informed consent forms; 2. patients who are critically ill, suffering from mental illness and cannot cooperate with the examination; 3. there are electronic implants, such as pacemakers and insulin pumps in the body, and magnetic metal foreign objects in the spot.

Keywords: prostate specific membrane antigen(pmsa) prostate cancer pet/ct
the profile of the depression and it's intervention strategy in patients with parkinson's disease in china

Conditions: Parkinson Disease

Summary: depression is considered to be the most common neuropsychiatric disturbance of pd. in this study, investigators will summarize the treatment profile of pd depression to see if pd depression is properly treated according to guideline.

depression is considered to be the most common neuropsychiatric disturbance of pd. prevalence rates of depressive disorders in parkinson's disease(pd) vary widely across studies, ranging from 2.7% to more than 90%. a systematic review of the 36 articles concerning pd and depression indicates that the weighted frequency of depressive pd was 52%. investigators' previous study on non-motor symptoms in 81 chinese pd patients demonstrated that prevalence of loss of interest and depression(sadness) were 48.7% and 36.7% by non-motor symptoms questionnaire (nmsquest) separately, which was similar to average global data. but another chinese data published in 2008 showed that the prevalence of depression in pd patients was only 12%, no statistical difference with controls(2%). thus, investigators plan to initiate a larger study to understand if pd depression in china is similar to it in western countries. depression would occur at the early stage of the disease or proceed the motor symptoms, usually accompanied with other non-motor symptoms including apathy, sleep disorder, cognitive impairment, and etc. the effects of depression on quality of life might refer to a wider range. there is lack of solid data to reveal the harm of depression on quality of life of pd patients and caregivers. in clinical practice, the disease burden of pd depression is usually underestimated by physicians and patients. although pd depression affects qol of patients and caregivers, pd depression would be relieved by medication, which was clearly recommended by international and chinese pd guidelines. but the pd depression treatment status in chinese clinical practice is not systematically analyzed before. in this study, investigator will summarize the treatment profile of pd depression to see if pd depression is properly treated according to guideline.

Eligibility criteria:
inclusion criteria: * the incidence of depression in patients of parkinson's disease (dsm-5 diagnostic criteria for depression) exclusion criteria: * inability to understand or answer questions for any reason，that would interfere our assessment. * participate in a concurrent clinical trial.
the accuracy of human endoscopic detection of submucosal invasive cancer in colorectal polyps

Conditions: Colorectal Polyp

Summary: colorectal cancer (crc) is a leading cause of death in the western world. it can be effectively prevented by removal of pre-malignant polyps (polypectomy) during colonoscopy. large (≥20mm) non-pedunculated colorectal polyps (lnpcps) represent 2-3% of colorectal polyps, and require special attention prior to treatment. if submucosal invasion (smi) is suspected careful decision making is required to exclude features which unacceptably increase the risk of lymph node metastases and render local treatment (endoscopic) non-curative. such patients require a multi-disciplinary approach and consideration of surgery +/- systemic therapy. recently the endoscopic imaging characteristics which precisely determine the risk of smi within colon polyps have been elucidated. this suggests endoscopic imaging may be the ideal investigation to stratify the presence and extent of smi within lnpcp, particularly as it can be applied in real-time at the time of planned endoscopic treatment. unfortunately, current classification systems are complex, require extensive training and technology not available in the majority of non-tertiary hospitals. they are therefore underused leading to incorrect decision making and negative patient outcome (e.g piecemeal resection without the chance of endoscopic cure or unnecessary further procedures in referral centres with resultant surgery anyway or surgery for benign disease) a simple clinical support tool was created, based on well-established parameters (i.e., presence of a demarcated area within a polyp, size of the polyp, paris classification, location within the colon and granularity) to identify overt (visible on the surface) and covert (hidden) submucosal invasion (smi) within lnpcps. crucially this tool only uses what is reproducible in the majority of endoscopy units in the western world (i.e. standard magnification, no extra chromic dyes etc). predict smi within lnpcps and we translated it into a single web-based clinical support tool that can be used by every endoscopist (expert and non-expert). to evaluate the tool, a survey will be send to participants. the survey consist of a 10-minute educational video where the use of the tool will be explained. then 20 standardised videos of lnpcps will be shown. participants are first asked about their first impression regarding the presence of smi. then they are redirected to the web-based tool. after filling the required data from a standardised video (45 seconds to minute, no focus on one particular area of the polyp) the score generated by our tool is copied to the participants computer clipboard and then pasted in the survey so that we could analyse it.


Eligibility criteria:
inclusion criteria: * gastrointestinal endoscopic experience (trainees, student, gastroenterologist consult, surgeon) exclusion criteria: * no connection with endoscopy in gastroenterology
preoxygenation using high flow oxygen : efficacy and tolerance in healthy volunteers

Conditions: Anesthesia; Airway Morbidity; Safety Issues

Summary: high flow nasal cannula oxygen has been proposed to perform preoxygenation in patients with acute respiratory failure requiring orotracheal intubation in intensive care units. however, its use for preoxygenation before the induction of general anaesthesia in operating room has never been evaluated in term of end tidal oxygen fraction which is the gold standard measurement during preoxygenation before general anaesthesia. the goal of the present study is to measure end tidal oxygen after 3 min of preoxygenation using the recommended method (spontaneous breathing of 100% inhaled oxygen through a face mask) and using high flow nasal canula oxygen, in healthy volunteers.

high flow nasal cannula oxygen has been proposed to perform preoxygenation in patients with acute respiratory failure requiring orotracheal intubation in intensive care units. the results suggest that high flow oxygen could be superior to bag reservoir face mask in term of occurrence of severe hypoxemia during the intubation procedure. at the present time its use for preoxygenation before the induction of general anaesthesia in operating room has never been evaluated in term of end tidal oxygen fraction which is the gold standard measurement ensuring that the functional residual capacity has been filled with oxygen. we planned a randomised cross over study in healthy volunteers studying efficacy and tolerance of preoxygenation using spontaneous ventilation with 100% inhaled oxygen through a face mask connected to the anaesthesia machine and preoxygenation using high flow nasal cannula oxygen (60l/min).

Eligibility criteria:
inclusion criteria: * healthy volunteers, * signed contentment exclusion criteria: * any chronic or acute disease, * pregnancy

Keywords: preoxygenation high flow oxygen
comparison between the analgesic efficacy of erector spinae plane block and psoas compartment block in hip surgery

Conditions: Hip Arthropathy

Summary: to evaluate the ability of erector spina plane block and psoas compartment block to decrease postoperative pain and analgesia requirements in patients undergoing hip surgery.

erector spina plane block or psoas compartment block will performed with guided ultrasound at l4 transverse process level would lead to adequate postoperative analgesia ,in total hip arthroplasty surgeries.

Eligibility criteria:
inclusion criteria: asa (american society of anesthesiologists) i- asa ii patients - exclusion criteria: * history of allergy to the study medication * refusal to participate

Keywords: erector spinae block hip arthroplasty postoperative analgesia psoas compartment block ultrasound
a trial of azithromycin sr for the treatment of mild to moderate community acquired pneumonia in japanese adults

Conditions: Pneumonia, Community-Acquired

Summary: to evaluate the clinical efficacy and safety in patients with mild or moderate community-acquired pneumonia receiving a dose of 2 g of azithromycin in the sr formulation.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed as mild or moderate in severity by the classification of pneumonia "clinical evaluation methods for new antimicrobial agents to treat respiratory infections: report of the committee for the respiratory system, japan society of chemotherapy (established in 2000)". exclusion criteria: * severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases. ("severe" assessed by the severity of underlying diseases and complications of "clinical evaluation methods for new antimicrobial agents to treat respiratory infections (draft)" by the japan society of chemotherapy (1997)).
study to evaluate immunogenicity and safety of glaxosmithkline (gsk) biologicals' quadrivalent influenza vaccine gsk2282512a when administered to children from 6 to 35 months of age

Conditions: Influenza

Summary: the purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine gsk2282512a (flu q-qiv) and compare its activity to sanofi pasteur's fluzone® (tiv) in children 6 to 35 months of age.

the subjects will be randomised (1:1) in the two treatment groups (q-qiv and tiv-yb) to explore response to vaccination.

Eligibility criteria:
inclusion criteria: * subjects' parent(s)/legally acceptable representative(s) \[lar(s)\] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol. * a male or female between, and including, 6 and 35 months of age at the time of the first vaccination. * written informed consent obtained from the parent(s)/lar(s) of the subject. * subjects in stable health as determined by investigator's clinical examination and assessment of subject's medical history. * subjects are eligible regardless of history of administration of influenza vaccine in a previous season. exclusion criteria: * use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. routine registered childhood vaccinations are permitted. * child in care. * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. for corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. inhaled and topical steroids are allowed. * prior receipt of any seasonal or pandemic influenza vaccine within six months preceding the first dose of study vaccine, or planned use during the study period. * administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. * history of guillain-barré syndrome within six weeks of receipt of prior influenza vaccine. * any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine. * acute disease and/or fever at the time of enrollment. * fever is defined as temperature ≥ 38.0°c/100.4°f by any method. * subjects with a minor illness without fever may be enrolled at the discretion of the investigator. * any significant disorder of coagulation or treatment with warfarin derivatives or heparin. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.

Keywords: children immunogenicity fluzone® 6 to 35 months of age seasonal influenza safety
a phase 1 study to evaluate the safety, tolerability, and immunogenicity of ub-313 in healthy participants

Conditions: Migraine

Summary: this first in-human (fih) study of ub-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected ub-313 dose regimens in healthy adults.

this is a single-site, randomized, double-blind, placebo-controlled, multidose regimen, fih study of ub-313, an anti-cgrp peptide-based immunotherapy candidate. the double-blind period will include dose escalation and cohort staggering for up to 4 planned dose levels of ub-313 or placebo in 4 cohorts of healthy participants. all eligible participants will be enrolled in the study for up to 44 weeks, consisting of im injections of ub-313 or placebo at week 0 (baseline, day 1), week 4, and week 12. the end of treatment (eot) is defined as week 16, followed by a follow-up period up to week 44.

Eligibility criteria:
inclusion criteria: * is a male or female aged 18 to 55 years old, inclusive, at time of informed consent. * has a body mass index between 18 and 30 kg/m2, inclusive at screening, and with a minimum weight of 50 kg. * male participants and their partners of childbearing potential must commit to the use of highly effective contraceptives for the study duration and for at least 12 weeks after the last dose. men must refrain from donating sperm during this same period. * female participants must be of nonchildbearing potential, or, for women of childbearing potential, must be willing to practice highly effective contraception throughout the duration of the study and for at least 24 weeks following the last dose. * other inclusion criteria apply exclusion criteria: * has a history of clinically significant medical or psychiatric conditions, which in the opinion of the investigator may compromise the participant's safety or the scientific value of the study, posing an unacceptable risk to the participant or interfere with the participant's ability to comply with study procedures or abide by study restrictions. * presents any concern by the investigator regarding safe participation in the study or for any other reason (including contraindication to mri) that the investigator considers the participant inappropriate for participation in the study. * has a recent history (within the past year of screening) of migraine headache. * has unsuitable skin characteristics for the dermal capsaicin challenge as determined by the investigator. * has not demonstrated at least a 100% increase in dermal blood flow following capsaicin challenge as part of screening procedures and measured through laser speckle contrast imaging. * other exclusion criteria apply
sexual quality of patients after bladder cancer cystectomy

Conditions: Sexual Dysfunction

Summary: bladder cancer is the second most prevalent urological cancer in france. about 1 in 5 new cases of bladder cancer infiltrate the muscles. the standard treatment is neoadjuvant chemotherapy followed by radical cystectomy associated with reconstruction of the urinary tract. the short-term effects on well-being and quality of life are well known. the long-term effects are, on the other hand, poorly understood, particularly sexual function. this study aim to asses the quality of sexual life in patients with cystectomy for bladder cancer. this will be done via various questionnaires given before and after surgery.

the study is a prospective observational cohort study of the quality of sexual life in patients with cystectomy for bladder cancer. data is collected via qlq-c30, eortc-shq22, mshq if male, female sexual function index (fsfi) questionnaires that the patients complete by themselves. they are given before surgery and then 8 months after surgery. the study consists of the compilation of relevant clinical data and questionnaire results.

Eligibility criteria:
inclusion criteria: * any adult patient who had a cystectomy for bladder cancer * affiliated with a social security scheme exclusion criteria: * no cystectomy * cystectomy for neurological etiology * pregnant or breastfeeding women

Keywords: bladder cancer cystectomy sex life sex quality
safety and effects of ramipril combined with candesartan

Conditions: Hypertension

Summary: we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.

forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

Eligibility criteria:
inclusion criteria: * patients with mild to moderate hypertension exclusion criteria: * we will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.

Keywords: endothelial function, insulin resistance, adipocytokines
effects of different deflation methods on coughing response and hemodynamics during extubation

Conditions: Deflating Method

Summary: patients with endotracheal intubation and general anesthesia often have severe choking and hemodynamic fluctuations during the extubation period, which increases the risk of cerebrovascular accident, arrhythmia, incision bleeding and so on . this study aimed to observe the effects of different methods of deflating of endotracheal tube cuffs on cough response and hemodynamics during periextubation in patients undergoing general anesthesia surgery.


Eligibility criteria:
inclusion criteria: 1. elective endotracheal intubation under general anesthesia. 2. operation time \< 3 h. 3. asa grade i or ii. 4. age 18\~65 years old. exclusion criteria: 1. throat and neck surgery. 2. those assessed to have a high risk of reflux aspiration. 3. difficulty intubation. 4. history of snoring before surgery. 5. recent respiratory illness such as chronic cough. 6. previous airway hyperresponsiveness, such as asthma. 7. recent use of cough suppressants. 8. patients with severe heart, liver and kidney diseases.

Keywords: deflating method extubation phase coughing reaction